The Hidden Forces Shaping Drug Costs: What HR Leaders Need to Know

For HR professionals, healthcare costs are not just a financial issue — they directly affect employee well-being, benefits strategy, and organizational competitiveness. While most discussions focus on insurance carriers and providers, two lesser-known players significantly influence both drug costs and access to care: contract research organizations (CROs) and pharmacy benefit managers (PBMs).

Understanding how these entities operate can help HR leaders make more informed decisions about benefits design, vendor selection, and long-term workforce health strategies.

Why Clinical Trials Matter to Employers

Before a drug ever reaches an employee’s prescription plan, it must go through clinical trials. This process increasingly relies on CROs — third-party firms that pharmaceutical companies hire to conduct and manage trials.

The HR Connection

At first glance, CROs may seem far removed from HR concerns. However, they play a key role in speed-to-market for new treatments, cost structures that influence pricing, and access to innovation for workforce health.

CROs allow pharmaceutical companies to convert fixed costs into scalable, project-based costs. This flexibility can accelerate drug development and reduce inefficiencies.

For HR leaders, this translates into a key insight: efficient clinical research can lead to faster access to new therapies — but not always lower costs.

Pharmacy Benefit Managers: The Gatekeepers of Drug Spending

If CROs influence how drugs are developed, PBMs play a central role in how those drugs are priced and accessed within employer-sponsored health plans.

PBMs act as intermediaries between employers, insurers, pharmacies, and pharmaceutical companies. For HR professionals managing benefits, benefits providers are often among the most important — and least transparent — partners.

Two Primary Revenue Models

1. Fee-for-Service model – Employers pay PBMs directly for services; this model is more transparent and predictable.

2. Spread pricing model – PBMs charge more than they reimburse pharmacies and keep the difference, which can obscure true costs.

Why This Matters for HR

Prescription drug spending is one of the fastest-growing benefit costs. The PBM model used can affect total program costs, employees' out-of-pocket expenses, plan transparency, and employee trust.

The Transparency Challenge

Transparency in drug pricing is a major concern. Fee-for-service models offer clarity, while spread pricing can obscure rebate flows and true costs, making it harder for HR to assess value.

Emerging Disruptions HR Should Watch

1. Direct clinical trial networks – Faster innovation and improved employee outcomes.

2. Transparent drug pricing models – Clearer pricing and potential cost savings.

3. Data-driven health ecosystems – Better population health and engagement.

Strategic Takeaways for HR Leaders

- Reevaluate PBM contracts and request transparency

- Align benefits with employee needs

- Monitor emerging market models

- Collaborate across finance and leadership teams

The Bottom Line

For HR professionals, healthcare strategy now requires understanding the full ecosystem behind drug development and pricing. CROs influence what treatments become available, and PBMs determine how those treatments are accessed and paid for.

As transparency increases and new models emerge, HR leaders can play a more strategic role in balancing cost control with employee well-being.

David G. Epstein, MHL, SHRM-SCP, is the director of human resources and talent strategy for Mobilization for Justice in New York City.